Therapeutic Drug Monitoring of Posaconazole: an Update

被引：146
作者：
Dekkers B.G.J. [1 ]
Bakker M. [2 ]
van der Elst K.C.M. [3 ]
Sturkenboom M.G.G. [1 ]
Veringa A. [1 ]
Span L.F.R. [2 ]
Alffenaar J.-W.C. [1 ]
机构：
[1] Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30.001, Groningen
[2] Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen
[3] Department of Clinical Pharmacy, ZGT Hospital Group Twente, Hengelo
来源：
Current Fungal Infection Reports | 2016年 / 10卷 / 2期
关键词：
Dried blood spot; Fusarium infections; Invasive aspergillosis; Invasive fungal infection; Mucormycosis; Pharmacodynamics; Pharmacokinetics; Posaconazole; Prophylaxis; Scedosporium infections; Therapeutic drug monitoring;
D O I：
10.1007/s12281-016-0255-4
中图分类号：
学科分类号：
摘要：
Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole. © 2016, The Author(s).
引用
收藏
页码：51 / 61
页数：10
相关论文
共 72 条
[1]  
Drew R.H., Townsend M.L., Pound M.W., Johnson S.W., Perfect J.R., Recent advances in the treatment of life-threatening, invasive fungal infections, Expert Opin Pharmacother, 14, pp. 2361-2374, (2013)
[2]  
Torres H.A., Hachem R.Y., Chemaly R.F., Kontoyiannis D.P., Raad I.I., Posaconazole: a broad-spectrum triazole antifungal, Lancet Infect Dis, 5, pp. 775-785, (2005)
[3]  
Wiederhold N., Patterson T., Emergence of azole resistance in Aspergillus, Semin Respir Crit Care Med, 36, pp. 673-680, (2015)
[4]  
Lipp H.-P., Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview, Br J Clin Pharmacol, 70, pp. 471-480, (2010)
[5]  
Li Y., Theuretzbacher U., Clancy C.J., Nguyen M.H., Derendorf H., Pharmacokinetic/pharmacodynamic profile of posaconazole, Clin Pharmacokinet, 49, pp. 379-396, (2010)
[6]  
Krishna G., Moton A., Ma L., Medlock M.M., McLeod J., Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers, Antimicrob Agents Chemother, 53, pp. 958-966, (2009)
[7]  
van der Elst K.C.M., Brouwers C.H.S., van den Heuvel E.R., van Wanrooy M.J.P., Uges D.R.A., van der Werf T.S., Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease, Ther Drug Monit, (2015)
[8]  
Chae H., Cho S.-Y., Yu H., Cha K., Lee S., Kim M., Et al., Determination of posaconazole concentration with LC–MS/MS in adult patients with hematologic malignancy, Clin Chim Acta, 450, pp. 220-226, (2015)
[9]  
Cojutti P., Candoni A., Simeone E., Franceschi L., Fanin R., Pea F., Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations, Antimicrob Agents Chemother, 57, pp. 6081-6084, (2013)
[10]  
Alffenaar J.-W.C., van Assen S., van der Werf T.S., Kosterink J.G.W., Uges D.R.A., Omeprazole significantly reduces posaconazole serum trough level, Clin Infect Dis, 48, (2009)
12345678